Trials / Recruiting
RecruitingNCT04743141
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant (PF-07899801) | Rimegepant 75 mg, 50 mg or 35 mg ODT |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2030-07-31
- Completion
- 2030-07-31
- First posted
- 2021-02-08
- Last updated
- 2026-04-16
Locations
126 sites across 3 countries: United States, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04743141. Inclusion in this directory is not an endorsement.